These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 25881697)

  • 1. [Synthetic lethal genes to mutant p53].
    Liu TY; Guo HQ; Zhu MY; Huang YZ; Jia ST; Luo Y; Zhang JH
    Yi Chuan; 2015 Apr; 37(4):321-326. PubMed ID: 25881697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting mutant p53 for cancer therapy: direct and indirect strategies.
    Hu J; Cao J; Topatana W; Juengpanich S; Li S; Zhang B; Shen J; Cai L; Cai X; Chen M
    J Hematol Oncol; 2021 Sep; 14(1):157. PubMed ID: 34583722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of potential synthetic lethal genes to p53 using a computational biology approach.
    Wang X; Simon R
    BMC Med Genomics; 2013 Sep; 6():30. PubMed ID: 24025726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements.
    Mizuarai S; Kotani H
    Hum Genet; 2010 Dec; 128(6):567-75. PubMed ID: 20976469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets.
    Mizuarai S; Irie H; Schmatz DM; Kotani H
    Curr Mol Med; 2008 Dec; 8(8):774-83. PubMed ID: 19075675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The cooperation between p53 and Ras in tumorigenesis].
    Wei YY; Hou J; Tang WR; Luo Y
    Yi Chuan; 2012 Dec; 34(12):1513-21. PubMed ID: 23262097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [p53 as a molecular target for cancer therapy].
    Ishioka C; Osada M; Gamo M; Kanamaru R
    Gan To Kagaku Ryoho; 1997 Dec; 24(15):2207-12. PubMed ID: 9422063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploiting synthetic lethal interactions for targeted cancer therapy.
    Reinhardt HC; Jiang H; Hemann MT; Yaffe MB
    Cell Cycle; 2009 Oct; 8(19):3112-9. PubMed ID: 19755856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recent advances in mutant p53 and novel personalized strategies for cancer therapy].
    Lu SQ; Jia ST; Luo Y
    Yi Chuan; 2011 Jun; 33(6):539-48. PubMed ID: 21684858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant p53: an oncogenic transcription factor.
    Strano S; Dell'Orso S; Di Agostino S; Fontemaggi G; Sacchi A; Blandino G
    Oncogene; 2007 Apr; 26(15):2212-9. PubMed ID: 17401430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploiting synthetic lethal interactions between DNA damage signaling, checkpoint control, and p53 for targeted cancer therapy.
    Morandell S; Yaffe MB
    Prog Mol Biol Transl Sci; 2012; 110():289-314. PubMed ID: 22749150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
    Stiewe T; Haran TE
    Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting mutant p53 for efficient cancer therapy.
    Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
    Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advances on mutant p53 research].
    Li DH; Zhang LQ; He FC
    Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis.
    Stein Y; Rotter V; Aloni-Grinstein R
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant p53 reactivation by small molecules makes its way to the clinic.
    Bykov VJ; Wiman KG
    FEBS Lett; 2014 Aug; 588(16):2622-7. PubMed ID: 24768524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant p53 in cancer: new functions and therapeutic opportunities.
    Muller PA; Vousden KH
    Cancer Cell; 2014 Mar; 25(3):304-17. PubMed ID: 24651012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcription regulation by mutant p53.
    Weisz L; Oren M; Rotter V
    Oncogene; 2007 Apr; 26(15):2202-11. PubMed ID: 17401429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disarming mutant p53 oncogenic function.
    Girardini JE; Marotta C; Del Sal G
    Pharmacol Res; 2014 Jan; 79():75-87. PubMed ID: 24246451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
    Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
    J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.